JPWO2019169283A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019169283A5 JPWO2019169283A5 JP2020545510A JP2020545510A JPWO2019169283A5 JP WO2019169283 A5 JPWO2019169283 A5 JP WO2019169283A5 JP 2020545510 A JP2020545510 A JP 2020545510A JP 2020545510 A JP2020545510 A JP 2020545510A JP WO2019169283 A5 JPWO2019169283 A5 JP WO2019169283A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- inhibitor
- combination drug
- subject
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 239000003112 inhibitor Substances 0.000 claims 25
- 229940000425 combination drug Drugs 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 18
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 17
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 claims 17
- 108010023082 activin A Proteins 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 230000037396 body weight Effects 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 238000001990 intravenous administration Methods 0.000 claims 4
- 238000007920 subcutaneous administration Methods 0.000 claims 4
- 210000003205 muscle Anatomy 0.000 claims 3
- 238000010521 absorption reaction Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000009977 dual effect Effects 0.000 claims 2
- 238000000691 measurement method Methods 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637017P | 2018-03-01 | 2018-03-01 | |
| US62/637,017 | 2018-03-01 | ||
| PCT/US2019/020330 WO2019169283A1 (en) | 2018-03-01 | 2019-03-01 | Methods for altering body composition |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021515003A JP2021515003A (ja) | 2021-06-17 |
| JP2021515003A5 JP2021515003A5 (https=) | 2022-02-18 |
| JPWO2019169283A5 true JPWO2019169283A5 (https=) | 2022-02-18 |
| JP7579706B2 JP7579706B2 (ja) | 2024-11-08 |
Family
ID=65763898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545510A Active JP7579706B2 (ja) | 2018-03-01 | 2019-03-01 | 体組成を変更するための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11248044B2 (https=) |
| EP (1) | EP3758800A1 (https=) |
| JP (1) | JP7579706B2 (https=) |
| KR (1) | KR20200128125A (https=) |
| CN (1) | CN111787981B (https=) |
| AU (2) | AU2019226551B2 (https=) |
| CA (1) | CA3092334A1 (https=) |
| EA (1) | EA202092064A1 (https=) |
| IL (2) | IL321873A (https=) |
| MA (1) | MA52417A (https=) |
| MX (2) | MX2020008991A (https=) |
| WO (1) | WO2019169283A1 (https=) |
| ZA (1) | ZA202004935B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012339722B2 (en) | 2011-11-14 | 2017-09-14 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A |
| TW201920262A (zh) * | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| WO2016168613A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| DK3773713T3 (da) | 2018-04-06 | 2025-08-18 | Regeneron Pharma | Leptinreceptoragonistantistof til anvendelse i forøgelse af knoglemasse hos et individ, der lider af metabolisk dysfunktion eller hypoleptinæmI |
| WO2021257947A1 (en) * | 2020-06-18 | 2021-12-23 | Regeneron Pharmaceuticals, Inc. | Activin a antibody formulations and methods of use thereof |
| WO2024108158A1 (en) * | 2022-11-18 | 2024-05-23 | Byomass Inc. | Anti-activin a/b antibodies and uses thereof |
| US20260000758A1 (en) * | 2024-06-28 | 2026-01-01 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DK0690873T3 (da) | 1993-03-19 | 2003-09-29 | Univ Johns Hopkins Med | Vækstdifferentieringsfaktor-8 |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| ES2330062T3 (es) | 1998-05-06 | 2009-12-03 | Metamorphix, Inc. | Procedimientos para tratar la diabetes por inhibicion de gdf-8. |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US7056512B1 (en) | 1999-07-20 | 2006-06-06 | Pharmexa A/S | Method for down-regulating GDF-8 activity |
| US6670140B2 (en) | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| BRPI0410927A (pt) | 2003-06-02 | 2006-06-27 | Wyeth Corp | métodos terapêuticos e profiláticos para distúrbios neuromusculares |
| CA2551877A1 (en) | 2003-12-31 | 2005-07-21 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| EP1729793B1 (en) | 2004-03-02 | 2015-07-22 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors for muscle wasting disorders |
| ATE557042T1 (de) | 2004-03-23 | 2012-05-15 | Lilly Co Eli | Anti-myostatin-antikörper |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| AU2005272646A1 (en) | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| NL1031674C2 (nl) | 2005-04-25 | 2007-04-26 | Pfizer | Antilichamen tegen myostatine. |
| CN102321174B (zh) | 2005-05-06 | 2013-10-16 | 津莫吉尼蒂克斯公司 | Il-31单克隆抗体及使用方法 |
| EP1773041A1 (en) | 2005-07-21 | 2007-04-11 | Chao-Hung Wu | Audio/video data transmission system using the internet to interconnect telephones |
| ES2534760T3 (es) | 2005-08-19 | 2015-04-28 | Wyeth Llc | Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8 |
| BRPI0616923A2 (pt) | 2005-10-06 | 2011-07-05 | Lilly Co Eli | anticorpos monoclonais, seus usos e composição farmacêutica |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| JP2009518422A (ja) | 2005-12-06 | 2009-05-07 | アムジェン インコーポレイテッド | ミオスタチン・アンタゴニストの使用 |
| US7972599B2 (en) | 2006-03-20 | 2011-07-05 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Immunomodulation of inflammatory conditions utilizing Follistatin-like protein-1 and agents that bind thereto |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| US8309068B2 (en) | 2006-08-03 | 2012-11-13 | Myostin Therapeutics Pty Ltd. | Isolated polypeptides and methods of improving muscle strength |
| CA2661836A1 (en) | 2006-09-05 | 2008-03-13 | Eli Lilly And Company | Anti-myostatin antibodies |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| EP2463282B1 (en) | 2007-11-05 | 2013-08-07 | Novartis AG | 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis |
| SMT202300222T1 (it) | 2008-08-14 | 2023-09-06 | Acceleron Pharma Inc | Trappole di gdf |
| AR074777A1 (es) | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
| US8138142B2 (en) | 2009-01-13 | 2012-03-20 | Acceleron Pharma Inc. | Methods for increasing adiponectin in a patient in need thereof |
| JP5766179B2 (ja) | 2009-04-27 | 2015-08-19 | ノバルティス アーゲー | 筋肉増殖を増加させるための組成物および方法 |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| JP6267425B2 (ja) | 2009-11-17 | 2018-01-24 | アクセルロン ファーマ， インコーポレイテッド | 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| UY33421A (es) | 2010-06-03 | 2011-12-30 | Glaxo Wellcome House | Proteinas de union al antígeno humanizados |
| US8999343B2 (en) | 2010-08-16 | 2015-04-07 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
| CN103298832A (zh) | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
| AU2012339722B2 (en) * | 2011-11-14 | 2017-09-14 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A |
| GR1007832B (el) | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| EP2861617A1 (en) | 2012-06-15 | 2015-04-22 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| SG10201706148WA (en) | 2013-02-01 | 2017-08-30 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
| TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| KR20160042987A (ko) | 2013-08-14 | 2016-04-20 | 노파르티스 아게 | 산발성 봉입체 근염을 치료하는 방법 |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| WO2016168613A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| WO2018009732A1 (en) | 2016-07-08 | 2018-01-11 | Regeneron Pharmaceuticals, Inc. | Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension |
-
2019
- 2019-03-01 CN CN201980016375.8A patent/CN111787981B/zh active Active
- 2019-03-01 IL IL321873A patent/IL321873A/en unknown
- 2019-03-01 CA CA3092334A patent/CA3092334A1/en active Pending
- 2019-03-01 US US16/290,287 patent/US11248044B2/en active Active
- 2019-03-01 JP JP2020545510A patent/JP7579706B2/ja active Active
- 2019-03-01 IL IL276921A patent/IL276921B2/en unknown
- 2019-03-01 KR KR1020207028353A patent/KR20200128125A/ko not_active Ceased
- 2019-03-01 EP EP19710966.3A patent/EP3758800A1/en active Pending
- 2019-03-01 WO PCT/US2019/020330 patent/WO2019169283A1/en not_active Ceased
- 2019-03-01 EA EA202092064A patent/EA202092064A1/ru unknown
- 2019-03-01 MA MA052417A patent/MA52417A/fr unknown
- 2019-03-01 MX MX2020008991A patent/MX2020008991A/es unknown
- 2019-03-01 AU AU2019226551A patent/AU2019226551B2/en active Active
-
2020
- 2020-08-11 ZA ZA2020/04935A patent/ZA202004935B/en unknown
- 2020-08-27 MX MX2025006615A patent/MX2025006615A/es unknown
-
2022
- 2022-01-06 US US17/570,128 patent/US20220119514A1/en not_active Abandoned
-
2024
- 2024-10-09 US US18/910,740 patent/US20250109191A1/en active Pending
-
2025
- 2025-05-06 AU AU2025203242A patent/AU2025203242A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021515003A5 (https=) | ||
| JP2022050618A5 (https=) | ||
| IL276921B1 (en) | Methods for altering body composition | |
| JP2018512435A5 (https=) | ||
| JP2022120009A (ja) | ベンラリツマブを使用して喘息の増悪率を低減する方法 | |
| JP2021514945A5 (https=) | ||
| JP2014502596A (ja) | パクリタキセルおよびトラスツズマブ−ｍｃｃ−ｄｍ１を用いたｈｅｒ２陽性癌の治療 | |
| JP2013520442A5 (https=) | ||
| JP2006316040A5 (https=) | ||
| JP6770312B2 (ja) | 骨疾患の治療 | |
| CN103732252B (zh) | 使用抗cd‑19抗体和氮芥的联合治疗 | |
| JPWO2018191479A5 (https=) | ||
| WO2012079093A2 (en) | Dosage and administration of bispecific scfv conjugates | |
| JPWO2019169283A5 (https=) | ||
| KR20200016868A (ko) | 항-cd19 adc의 투여를 위한 투약량 체제 | |
| JP2022184998A (ja) | 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ | |
| JP2023138982A (ja) | インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を治療する方法 | |
| CA3032542A1 (en) | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor | |
| JPWO2019246356A5 (https=) | ||
| JP2018533588A (ja) | 治療パラダイム | |
| JP2020520905A5 (https=) | ||
| CN120344271A (zh) | 抗her2抗体药物偶联物治疗乳腺癌 | |
| JP2025516723A (ja) | インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を選択的に治療する方法 | |
| JP2024531220A (ja) | Ｔｉｇｉｔアンタゴニスト、ｐｄ－１アンタゴニスト、及びレンバチニブを含む治療薬の組み合わせ | |
| WO2016003789A1 (en) | Combination therapy |